Stage IIIB Skin Melanoma Completed Phase 3 Trials for Teceleukin (DB15389)

IndicationStatusPhase
DBCOND0029534 (Stage IIIB Skin Melanoma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00019682Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaTreatment